

Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis

Information for the public
Published: 27 March 2024

www.nice.org.uk

Daratumumab (Darzalex) in combination with bortezomib, cyclophosphamide and dexamethasone is available on the NHS. It is a possible treatment for newly diagnosed systemic amyloid light-chain (AL) amyloidosis in adults.

Daratumumab should be stopped after 24 cycles of treatment or earlier if the condition gets worse.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on amyloidosis](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Myeloma UK](#), 0800 980 3332
- [Cardiomyopathy UK](#), 0800 018 1024

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5852-8